Navigation Links
VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven
Date:3/20/2008

and consistent with our stated objectives, we have identified and negotiated a strategic transaction worthy of the application of VaxGen resources, and presented it to our stockholders for approval.

Similarly, Raven has continued to make excellent progress with its platform technology and clinical pipeline. Specifically, Raven's recent progress includes the following:
-- On February 12th, Raven announced that four scientific abstracts

pertaining to its clinical and pre-clinical programs had been accepted

for presentation at the April meeting of the American Academy of Cancer

Research.

-- Following the completion of enrollment in the Phase 1/2a trial of its

lead clinical candidate RAV12 in mid-February, Raven announced on March

11th that the study results had been accepted for presentation at the

American Society of Clinical Oncology in May.

-- On March 13th, Raven announced that it had initiated a Phase 2 study of

RAV12 for the treatment of patients with metastatic pancreatic cancer.

These and other scientific presentations and announcements can be found on Raven's corporate website.

VaxGen believes that as the Raven research and development programs continue to progress and become more visible, the value of its discovery platform and potential oncology therapeutics will become increasingly evident. We further believe that the combination of Raven's science, discovery platforms and pipeline with VaxGen's late stage recombinant protein development, manufacturing expertise and financial resources will have a synergistic effect, enabling this promising pipeline to progress.

A few VaxGen stockholders continue to express opposition to the merger, and it has come to our attention that there is commentary circulating which is not factually correct. We are deeply concerned at this development and believe that our stockholders deserve the opportunity to make an
'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. USAID Provides Additional Wildfire Assistance to Greece
5. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
6. New knock-out gene model provides molecular clues to breast cancer
7. PreMD Provides Update on 510(k) Application for PREVU(x) POC
8. SIV infection of natural hosts provides new insights into HIV disease complexity
9. Microarray provides 3 genomic guides to breast cancer treatment decisions
10. Access Innovations Provides Support Services for Agis Network
11. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Pirate Jonny's Caribbean BBQ Rubs, ... new recipe cards, fun t-shirts, and caps for consumers ... Clearwater, Florida, Pirate Jonny, aka, Jonathan Toner, founder, decided ... to three recipes featuring different flavors of the Caribbean, ... website. The recipe cards will feature "easy to ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Braverman Eye ... in Fort Lauderdale at the most affordable fee. They ... eyesight through their advanced Lasik treatments. LASIK is a ... the Braverman Eye Center has been delivering successful LASIK ... live a glasses-free and contact lenses-free life with the ...
(Date:8/22/2014)... Alzheimer,s disease can be slowed and some of ... is found in pomegranate. Also, the painful ... and Parkinson,s disease could be reduced, according to ... University of Huddersfield scientist Dr Olumayokun Olajide, who ... , Now, a new phase of research can ...
(Date:8/22/2014)... The ALS Association, along with its Western Pennsylvania ... Health Network as a Certified Treatment Center of ... (AGH), is the only ALS treatment program in western ... highest levels of established national standards of care in ... to as Lou Gehrig’s Disease. , Allegheny Health Network’ ...
(Date:8/22/2014)... (HealthDay News) -- The U.S. Drug Enforcement Administration (DEA) ... containing hydrocodone, which has been tied to a surge ... new restrictions would cover prescription narcotic drugs such as ... the same regulatory class as painkillers such as Oxycontin, ... to a three-month supply of the drug and will ...
Breaking Medicine News(10 mins):Health News:Pirate Jonny's Caribbean BBQ Rubs, Seasonings & Sauces Get New Look by Hoisting New Recipe Card Creations and New Clothing Apparel for its Logos 2Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 3Health News:U.S. to Tighten Access to Certain Narcotic Painkillers 2Health News:U.S. to Tighten Access to Certain Narcotic Painkillers 3
... INDIANAPOLIS, July 1 CoLucid Pharmaceuticals, Inc., ... central nervous,system disorders, announced it closed a ... Capital led the round, which included previous ... Funds and,Triathlon Medical Ventures. The financing will ...
... Conn., July 1 The organic food that ... intended and often,contains more nutrients than its counterpart., ... the popularity of organic food on the rise, ... more accessible than ever., "The difference between ...
... USB duplicator with copy protection and digital rights management features available ... Only partitions, Autorun support, copy and paste restriction and document printing ... ... (PRWEB) July 1, 2008 -- Nexcopy Inc., a leading manufacturer in ...
... can be overwhelming; Allsup provides tips on getting prepared to file ... ... Every day, people across the United States must stop working because ... challenges when faced with these circumstances can be overwhelming, including where ...
... Researchers have developed a series of tests that for the ... and smell (olfactory function) in young children, according to a ... Otolaryngology Head and Neck Surgery . , The study, ... 5-7 can identify a majority of 16 different test odorants ...
... showing that psilocybin, a substance contained in "sacred mushrooms," ... that those beneficial effects appear to last more than ... of Psychopharmacology , the Johns Hopkins researchers note that ... controlled conditions in a Hopkins study published in 2006, ...
Cached Medicine News:Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 2Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 3Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 4Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Go Organic for Quality, Natural Food 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Go Organic for Quality, Natural Food 3Health News:Figure Skater Peggy Fleming Teams With HealthSaver: Go Organic for Quality, Natural Food 4Health News:World's First USB Duplicator with Copy Protection and Digital Rights Management Available from Nexcopy and TrusCont Ltd. 2Health News:World's First USB Duplicator with Copy Protection and Digital Rights Management Available from Nexcopy and TrusCont Ltd. 3Health News:Two Categories of Information Are Key in Seeking SSDI Benefits 2Health News:Two Categories of Information Are Key in Seeking SSDI Benefits 3Health News:Two Categories of Information Are Key in Seeking SSDI Benefits 4Health News:Spiritual effects of hallucinogens persist, Johns Hopkins researchers report 2
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... MISSION, Kan. , Aug. 21, 2014 /PRNewswire-iReach/ ... Information Trust Alliance (HITRUST) under its Common Security ... ScriptPro,s Enterprise Security and Privacy Manager, "We appreciate ... the level of commitment that this certification signifies. ... compliant." ABOUT THE CSF CERTIFICATION PROCESS: ...
(Date:8/21/2014)... , August 21, 2014 ... BreedIT Ltd., the exclusive worldwide license holder and ... plant breeders and researchers, today is pleased to ... venture with Seach Ltd, a leading Israeli medical ... research and develop new breeds of medical Cannabis ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... 6 TargeGen, Inc. today announced that,the Company,s ... and the,Company plans to initiate a multi-center clinical ... highly selective JAK2 inhibitor in,January, 2008. Additionally, TargeGen ... will be made at the 2007 ASH Conference,(Atlanta, ...
... Inc. (Nasdaq: BCRX ) today provided an ... Forodesine HCl Data to be Presented at American ... Chair, Dermatology, The University of,Texas M.D. Anderson Cancer ... Phase I/II clinical study of oral forodesine HCl ...
Cached Medicine Technology:TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH 2BioCryst Provides Forodesine HCl Update 2BioCryst Provides Forodesine HCl Update 3BioCryst Provides Forodesine HCl Update 4BioCryst Provides Forodesine HCl Update 5
55 DSL's new collection of optical frames has established a strong personality and developed,superficial retro concepts with contemporary styles and strong impacting colours....
... and highly sought-after, the ... collection of sunglasses and ... the very latest men's ... timeless sources of inspiration ...
... Extended Ablation laser enables the physician to provide ... results and no downtime., The new Whisper NG ... an extra long pulse width to achieve "Extended ... over 3-5 days, and occurs simultaneously with the ...
... the art software package designed to assist in ... by a lens manufacturer with years of experience ... is designed to help you run your lab ... the software dictates., ,Designed specifically for integrated retail ...
Medicine Products: